Clinical trials: Moderate Plaque Psoriasis
Psoriasis
Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and effectiveness of CNDO 201Trichuris suis ova (TSO) for the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT01836939
- Testing
- TSO 2500, TSO 7500
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Mark Lebwohl
Plaque Psoriasis
The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab
To describe the response of etanercept after adalimumab has failed to produce a satisfactory response in moderate to severe plaque psoriasis.
- Trial name
- NCT00833729
- Testing
- etanercept
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dermatrials Research
Plaque Psoriasis, Psoriatic Arthritis
Modifying PEST for Psoriatic Arthritis Screening
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
- Trial name
- ScreenX (NCT06382051)
- Testing
- PEST Screening group
- Where
- 30 sites in Canada
- Volunteers
- 502 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Healthy
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people.
- Trial name
- NCT07850310
- Testing
- MK-8644
- Where
- Australia
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
This will be a single-center, open-label clinical study to determine the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis vulgaris in skin of color (SOC) (FST IV-VI).
- Trial name
- NCT04571567
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Saakshi Khattri
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
This is Part 1 of a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 was administered to participants; Part 1 in healthy volunteers and Part 2 in psoriatic participants.
- Trial name
- NCT03724292
- Testing
- VTP-43742
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Chronic Plaque Psoriasis
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly…
- Trial name
- NCT07337434
- Testing
- Methotrexate, Apremilast
- Where
- Pakistan
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Syeda Sana Zaman
Psoriasis
The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis
The purpose of this study is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people.
- Trial name
- NCT02622386
- Testing
- Riboflavin
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Plaque Psoriasis
Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis
The study seeks to show whether there is additional benefit of using Lexette and Sorilux in the beginning of the treatment, and then maintenance treatment of Sorilux alone in moderate plaque type psoriasis patients.
- Trial name
- NCT04571151
- Testing
- LEXETTE 0.05% Topical Foam, Sorilux 0.005 % Topical Foam, Vehicle Foam
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Skin Sciences, PLLC
Moderate to Severe Plaque Psoriasis
Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects
This is a first-in-human, phase 1, single-center, randomized, double blinded, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, of 608 following subcutaneous injection in healthy subjects.
- Trial name
- NCT04367441
- Testing
- 608
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Moderate to Severe Psoriasis
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
This is a single-center, open-label, pilot study. A total of 18 subjects will be enrolled in this 6 month study to evaluate whether the response to intralesional alefacept injections prior to the standard course of…
- Trial name
- NCT00678470
- Testing
- Intralesional Alefacept
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Moderate to Severe Chronic Plaque Psoriasis
This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).
This is an open-label, 2-arm parallel-group study in normal healthy subjects to evaluate pharmacokinetics, safety, tolerability of Bmab 1200 -autoinjector (AI) after single subcutaneous injection (45 mg) in comparison with Bmab…
- Trial name
- NCT06738277
- Testing
- Bmab 1200 (Biosimilar Ustekinumab)
- Where
- India
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Biocon Biologics UK Ltd
Psoriasis
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
This is a single-center, open-label, pilot study. A total of 30 subjects (15 in each study arm) will be enrolled in this 6 month study to evaluate whether the addition of narrow band UVB (NB-UVB) phototherapy can enhance the…
- Trial name
- NCT00800982
- Testing
- Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Psoriasis
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
- Trial name
- AMAGINE-3 (NCT02786732)
- Testing
- 210mg Brodalumab, 140mg Brodalumab, Ustekinumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MedDerm Associates
Plaque Psoriasis
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045%…
- Trial name
- NCT05282771
- Testing
- Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
- Where
- United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.
- Trial name
- NCT02785185
- Testing
- IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion
- Where
- 13 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis
The primary objective is to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.
- Trial name
- NCT00333034
- Testing
- Etanercept
- Where
- 23 sites in Austria, Belgium and 8 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer